Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Visualizing Differences in Ligand Regulation of Wild-Type and Constitutively Active Mutant β2-Adrenoceptor-Green Fluorescent Protein Fusion Proteins

Alison J. McLean, Nicola Bevan, Stephen Rees and Graeme Milligan
Molecular Pharmacology December 1999, 56 (6) 1182-1191; DOI: https://doi.org/10.1124/mol.56.6.1182
Alison J. McLean
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Bevan
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Rees
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graeme Milligan
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Fusion proteins were generated by attachment of green fluorescent protein (GFP) to the C-terminal tail of either the wild-type human β2-adrenoceptor or a form with enhanced constitutive activity. Sustained treatment of HEK293 cells stably expressing the constitutively active mutant (CAM) β2-adrenoceptor-GFP with the inverse agonist betaxolol resulted in a marked up-regulation of the fusion protein that could be monitored by both fluorescence and immunoblotting of membrane fractions. This was not observed for the wild-type β2-adrenoceptor-GFP. Addition of the agonist isoprenaline to CAM β2-adrenoceptor-GFP expressing cells previously treated with betaxolol resulted in rapid internalization of the receptor into punctate intracellular vesicles in a manner similar to wild-type β2-adrenoceptor-GFP. A range of “β-blockers” replicated the up-regulation of the CAM β2-adrenoceptor-GFP, although pharmacological specificity was maintained, as it was not produced by α1- and α2-adrenoceptor-selective antagonists/inverse agonists. Parallel intact cell binding studies with [3H]dihydroalprenolol confirmed up-regulation of the CAM β2-adrenoceptor-GFP by betaxolol but failed to predict the optically monitored up-regulation produced by high concentrations of alprenolol. The cellular distribution of the up-regulated CAM β2-adrenoceptor-GFP was not identical after sustained treatment of the cells with different β-blockers. Inverse agonists, able to reduce basal intracellular cAMP levels, such as betaxolol and ICI118551, resulted in both increased plasma membrane receptor and increased diffuse intracellular staining. In contrast, treatment with labetolol and alprenolol resulted in a significant fraction of the intracellular receptor displaying a punctate distribution pattern. These ligands displayed substantial agonism to stimulate intracellular cAMP levels via the CAM β2-adrenoceptor-GFP.

Footnotes

    • Received July 19, 1999.
    • Accepted September 21, 1999.
  • Send reprint requests to: Dr. Graeme Milligan, Davidson Bldg., University of Glasgow, Glasgow G12 8QQ, Scotland, UK. E-mail:g.milligan{at}bio.gla.ac.uk

  • Financial support for this work was provided by the Medical Research Council and the European Union Biomed II program, Inverse Agonism: Implications for Drug Design. A.J.M. received a studentship from the Biotechnology and Biosciences Research Council.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 56 (6)
Molecular Pharmacology
Vol. 56, Issue 6
1 Dec 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Visualizing Differences in Ligand Regulation of Wild-Type and Constitutively Active Mutant β2-Adrenoceptor-Green Fluorescent Protein Fusion Proteins
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Visualizing Differences in Ligand Regulation of Wild-Type and Constitutively Active Mutant β2-Adrenoceptor-Green Fluorescent Protein Fusion Proteins

Alison J. McLean, Nicola Bevan, Stephen Rees and Graeme Milligan
Molecular Pharmacology December 1, 1999, 56 (6) 1182-1191; DOI: https://doi.org/10.1124/mol.56.6.1182

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Visualizing Differences in Ligand Regulation of Wild-Type and Constitutively Active Mutant β2-Adrenoceptor-Green Fluorescent Protein Fusion Proteins

Alison J. McLean, Nicola Bevan, Stephen Rees and Graeme Milligan
Molecular Pharmacology December 1, 1999, 56 (6) 1182-1191; DOI: https://doi.org/10.1124/mol.56.6.1182
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
  • Secretin Amino-Terminal Structure-Activity Relationships and Complementary Mutagenesis at the Site of Docking to the Secretin Receptor
  • LYN Kinase and Tyrosine Kinase Inhibitors Regulate OATP1B3
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics